The protective efficacy and immunogenicity of a chimeric
peptide against West Nile virus (WNV) was evaluated. This virus is the aetiological agent of
West Nile fever, which has recently emerged in the western hemisphere. The rapid spread of WNV throughout North America, as well as the constantly changing epidemiology and transmission of the virus by
blood transfusion and
transplantation, have raised major public-health concerns. Currently, there are no effective treatments for WNV or
vaccine for human use. We previously identified a novel, continuous
B-cell epitope from domain III of the WNV envelope
protein, termed Ep15. To test whether this
epitope can protect against
WNV infection, we synthesized a linear chimeric
peptide composed of Ep15 and the
heat-shock protein 60 peptide, p458. The p458
peptide is an effective carrier
peptide for
subunit vaccines against other infectious agents. We now report that mice immunized with the chimeric
peptide, p458-Ep15, were resistant to lethal challenges with three different WNV strains. Moreover, their brains were free of viral genome and infectious virus. Mice immunized with Ep15 alone or with p431-Ep15, a control conjugate, were not protected. The chimeric p458-Ep15
peptide induced WNV-specific
immunoglobulin G antibodies that neutralized the virus and induced the secretion of
interferon-gammain vitro. Challenge of chimeric
peptide-immunized mice considerably enhanced WNV-specific
neutralizing antibodies. We conclude that this chimeric
peptide can be used for formulation of a human
vaccine against WNV.